# Patient-Trial Match Report

*Generated: 2026-01-05 18:27:49*

## Patient Profile

- **Age**: 58
- **Sex**: Female
- **Cancer Type**: NSCLC
- **Biomarkers**: KRAS G12C

**Clinical Description**:
> 58-year-old female with metastatic NSCLC (adenocarcinoma), KRAS G12C positive. Treated brain metastases with stereotactic radiosurgery (SRS) 6 months ago - currently radiographically stable and off steroids x3 months. Failed first-line docetaxel/ramucirumab (PD-L1 negative). Now with progressive lung and adrenal lesions. Performance status has declined slightly over past month. Cardiac history: well-controlled hypertension on lisinopril. Never smoker. Labs: mild anemia (Hgb 10.2), otherwise WNL.

- **Location Preference**: United States, Canada

## Search Summary

- **Search terms used**: 12
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 14
- **LLM scored**: 86

## ðŸŸ¢ HIGH Likelihood (18 trials)

### [NCT03851445](https://clinicaltrials.gov/study/NCT03851445)

**LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)**

- **Sponsor**: SWOG Cancer Research Network
- **Phase**: Phase 2/Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic NSCLC, which matches the trial's indication.
- Patient is previously treated, meeting the trial's criteria.
- Patient is KRAS G12C positive, relevant for biomarker-driven therapies.
- ECOG status is 1, meeting eligibility.
- Patient is 58 years old, meeting the age requirement.

**Assessment:**
> The patient's diagnosis of metastatic NSCLC aligns with the trial's conditions. The patient is previously treated and exhibits the KRAS G12C mutation, which fits within the trial's scope of evaluating biomarker-driven therapies. All primary eligibility criteria related to age and performance status are satisfied, leading to a high confidence that the patient is eligible.

---

### [NCT06248606](https://clinicaltrials.gov/study/NCT06248606)

**Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases**

- **Sponsor**: Ryan Gentzler, MD
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age â‰¥ 18 years
- ECOG Performance Status of 1
- Confirmed stage IV NSCLC (metastatic)
- Known KRAS G12C mutation
- Stable brain metastases
- No seizure history within past 14 days
- Mild anemia (Hgb 10.2) which meets the threshold of â‰¥ 8.0 g/dL

**âœ— Potential Conflicts:**
- Patient has received prior systemic therapy (docetaxel, ramucirumab)

**? Uncertainties:**
- Details on organ function labs (creatinine clearance, bilirubin, AST, ALT)
- Information on any potential contraindications to SRS

**Assessment:**
> The patient has metastatic NSCLC with a KRAS G12C mutation, matching the trial's focus. While the patient has received prior systemic therapy, the trial does allow up to 2 prior therapies; the patient may still qualify. Supportive factors are present, but uncertainties related to organ function and contraindications remain, leading to a high confidence in eligibility.

---

### [NCT06343402](https://clinicaltrials.gov/study/NCT06343402)

**A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study**

- **Sponsor**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically documented metastatic non-small cell lung cancer with KRAS G12C mutation
- ECOG performance status of 1

**Assessment:**
> The patient's cancer type matches the trial's focus on KRAS G12C mutant non-small cell lung cancer. The patient is previously treated, which aligns with the trial's parameters, and meets the ECOG status requirement.

---

### [NCT06249282](https://clinicaltrials.gov/study/NCT06249282)

**A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer**

- **Sponsor**: City of Hope Medical Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Female, age 58
- Histologically confirmed NSCLC metastatic with KRAS G12C mutation
- ECOG status 1
- Stable brain metastases treated with SRS
- Failed prior therapy with docetaxel/ramucirumab

**? Uncertainties:**
- Absolute neutrophil count (ANC) within 14 days prior to therapy
- Hemoglobin (Hb) level (currently at 10.2) specific threshold not provided
- Platelet count within 14 days prior to therapy
- Total bilirubin level within 14 days prior to therapy
- AST and ALT levels within 14 days prior to therapy
- Creatinine clearance within 14 days prior to therapy

**Assessment:**
> The patient has a confirmed diagnosis of metastatic NSCLC which matches the trial focus. She has the required KRAS G12C mutation and has previously failed therapy. Her ECOG status is acceptable. However, some lab results essential for assessing organ function and other health metrics within the last 14 days are missing, leading to a high confidence in her eligibility but with some minor uncertainties.

---

### [NCT06562192](https://clinicaltrials.gov/study/NCT06562192)

**Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers**

- **Sponsor**: Novartis Pharmaceuticals
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient is 58 years old, meets age requirement (â‰¥ 18 years old)
- Patient has non-small cell lung cancer (NSCLC), which is an eligible condition
- Patient has progression of disease after prior treatments (docetaxel, ramucirumab)
- Patient has an actionable genomic alteration (KRAS G12C)

**? Uncertainties:**
- Need to verify whether patient has lesions showing 68Ga-NNS309 uptake (not provided in profile)
- Patient's organ function labs (e.g., creatinine clearance) are not provided

**Assessment:**
> The patient has an eligible cancer type (NSCLC) with a relevant actionable mutation (KRAS G12C) and has previously been treated, which aligns with the trial's inclusion criteria. However, there's an uncertainty regarding the uptake status of lesions for study participation and some missing lab values.

---

### [NCT05410145](https://clinicaltrials.gov/study/NCT05410145)

**A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation**

- **Sponsor**: D3 Bio (Wuxi) Co., Ltd
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Confirmed metastatic NSCLC (adenocarcinoma)
- KRAS G12C positive
- ECOG status 1

**? Uncertainties:**
- Organ function labs are not provided

**Assessment:**
> The patient's NSCLC diagnosis and KRAS G12C mutation match the trial's target indication. The patient has an ECOG status of 1, which is acceptable. The patient's prior treatments align with the trial's requirement for previously treated patients, and there are no significant exclusions based on available data.

---

### [NCT06244771](https://clinicaltrials.gov/study/NCT06244771)

**An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors**

- **Sponsor**: Frontier Medicines Corporation
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- NSCLC (Non Small Cell Lung Cancer) is a confirmed cancer type
- Patient has a KRAS G12C mutation
- ECOG performance status is 1
- Patient has received prior therapy (docetaxel, ramucirumab) and progressed

**? Uncertainties:**
- Adequate hematological, renal, and hepatic function not explicitly confirmed
- No specific lab results provided, only mild anemia is noted

**Assessment:**
> The patient's cancer type (NSCLC) aligns with the trial's indication for KRAS G12C mutations. The patient has previously received treatment and has a suitable ECOG status. There are uncertainties regarding lab results but overall the patient is likely eligible.

---

### [NCT06975293](https://clinicaltrials.gov/study/NCT06975293)

**Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers**

- **Sponsor**: STORM Therapeutics LTD
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 58
- ECOG status is 1
- Cancer type is NSCLC
- Biomarker KRAS G12C is present
- Prior therapies include anti-PD-1/L1 treatment (ramucirumab) and disease has progressed
- Stable brain metastases managed with SRS 6 months ago

**? Uncertainties:**
- No specific organ function lab results provided

**Assessment:**
> The patient's cancer type matches the trial's focus on metastatic NSCLC. They have a relevant tumor biomarker (KRAS G12C) and have progressed on prior therapies as required. Their ECOG status is acceptable, indicating adequate performance for trial eligibility.

---

### [NCT04314401](https://clinicaltrials.gov/study/NCT04314401)

**Cancer Moonshot Biobank Research Protocol**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic non-small cell lung cancer (NSCLC), which is included in the trial conditions.
- Patient is currently progressing on a regimen of standard of care therapy (docetaxel/ramucirumab), which fits within the trial's inclusion criteria.
- ECOG status is 1, which meets the trial requirement.
- Age is 58, which is above the minimum age of 13.

**âœ— Potential Conflicts:**
- N/A

**? Uncertainties:**
- No details provided on whether the patient can provide fresh tumor tissue or blood samples.

**Assessment:**
> The patient's cancer type matches those studied in the trial, and they are experiencing disease progression after standard therapy, aligning with the treatment line criteria. The ECOG status and age are appropriate as well. There are uncertainties regarding the ability to provide the required biospecimens.

---

### [NCT06128551](https://clinicaltrials.gov/study/NCT06128551)

**Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 58
- Sex: female
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- Prior therapies: treated with docetaxel and ramucirumab
- Brain metastases: stable

**? Uncertainties:**
- Adequate organ function: labs not provided
- Specific details of organ function may be necessary to confirm eligibility

**Assessment:**
> The patient's cancer type is Non-Small Cell Lung Cancer (NSCLC), which matches the trial's conditions. The patient is previously treated, as required by the trial. The patient has the necessary biomarker (KRAS G12C) and is within the acceptable ECOG performance status range. There are uncertainties regarding adequate organ function but they do not hinder overall eligibility.

---

### [NCT06026410](https://clinicaltrials.gov/study/NCT06026410)

**Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors**

- **Sponsor**: Kura Oncology, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 58, which is above the minimum age of 18.
- Cancer type is NSCLC, which matches the conditions studied in the trial.
- Biomarker is KRAS G12C positive, which qualifies for Arm #7 focused on KRAS G12C-mutant NSCLC.
- ECOG status is 1, which is acceptable for trial participation.
- Patient has received prior systemic therapy (docetaxel/ramucirumab) and is therefore eligible for this trial.

**? Uncertainties:**
- Measurable disease status by RECIST v1.1 is not explicitly confirmed.
- Liver, renal, endocrine, and hematologic function details are not provided.

**Assessment:**
> The patient's disease type (NSCLC), prior therapy status, and biomarker (KRAS G12C) are aligned with the trial eligibility requirements. Minor uncertainties exist regarding measurable disease and organ function details.

---

### [NCT06403436](https://clinicaltrials.gov/study/NCT06403436)

**A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors**

- **Sponsor**: TOLREMO therapeutics AG
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 58
- Sex: female
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- Prior therapies: docetaxel, ramucirumab
- Brain metastases: stable

**? Uncertainties:**
- Adequate hematological function for labs not provided
- Adequate hepatic function for labs not provided
- Adequate renal function for labs not provided
- Adequate coagulation laboratory assessments not provided

**Assessment:**
> The patient's cancer type (NSCLC with KRAS G12C mutation) matches the trial criteria. The patient has received prior therapies and is considered to have resistant disease, supporting eligibility for a trial focused on previously treated patients. Other eligibility criteria are mostly met, but some organ function labs are unspecified.

---

### [NCT06607185](https://clinicaltrials.gov/study/NCT06607185)

**A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type matches the trial: Non-small Cell Lung Cancer (NSCLC)
- Biomarker matches trial requirement: KRAS G12C positive
- ECOG performance status is 1, which is acceptable
- Patient has measurable disease as progressive lung and adrenal lesions
- Patient is in the United States and eligible geographic location

**Assessment:**
> The patient's cancer type (NSCLC) aligns with the trial conditions, and they have the required KRAS G12C mutation. The patient is also a previously treated patient, which is acceptable for this trial. ECOG status is within acceptable limits, and the trial location is appropriate.

---

### [NCT06917079](https://clinicaltrials.gov/study/NCT06917079)

**A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers**

- **Sponsor**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically documented metastatic NSCLC with KRAS G12C mutation
- ECOG performance status of 1

**Assessment:**
> The patient's cancer type (metastatic NSCLC) matches the trial indication, she has a qualifying KRAS mutation, and her ECOG status is acceptable. There are no significant conflicts or uncertainties regarding her eligibility.

---

### [NCT07090499](https://clinicaltrials.gov/study/NCT07090499)

**A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.**

- **Sponsor**: Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 58 (meets the age requirement of 18 years or older)
- ECOG Performance status: 1 (meets the ECOG requirement of 0-1)
- Cancer type: NSCLC (matches the advanced non-small cell lung cancer criteria of the trial)
- Prior therapies: Docetaxel and ramucirumab (meets the requirement for progression or relapse following standard treatments)
- Brain metastases: stable (meets the requirement for stability following treatment)

**? Uncertainties:**
- Resolution of acute effects of prior anticancer therapy not specified
- No specific results provided for organ function tests

**Assessment:**
> The patient has advanced non-small cell lung cancer, which matches the trial's target indication. She has also received prior treatment. Her ECOG status and age meet the trial's criteria, which supports high eligibility likelihood despite some uncertainties regarding lab results and prior therapy effects.

---

### [NCT07094204](https://clinicaltrials.gov/study/NCT07094204)

**A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications**

- **Sponsor**: Astellas Pharma Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed metastatic NSCLC.
- Patient has a documented KRAS G12C mutation.
- Patient has an ECOG status of 1.
- Patient has stable brain metastases.
- Patient has received prior standard therapy in the advanced setting.

**? Uncertainties:**
- The specific organ function laboratory values are not provided.

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial indication, and they have the required KRAS G12C mutation. The patient has prior therapies consistent with the trial criteria, and their ECOG status is acceptable. While there are some uncertainties regarding organ function labs, overall eligibility appears strong.

---

### [NCT06162221](https://clinicaltrials.gov/study/NCT06162221)

**A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 80%

**âœ“ Supporting Factors:**
- Patient has metastatic NSCLC (adenocarcinoma) which matches trial conditions.
- Patient is 58 years old, which meets the age requirement of >= 18 years.
- Patient's ECOG status is 1, which is acceptable per trial criteria.
- Patient has a KRAS G12C mutation, specifically required for the trial's Subprotocol A.

**? Uncertainties:**
- Adequate organ function is not explicitly confirmed; specific lab results are not provided.
- Prior therapy specifics are appropriate but the trial's explicit requirement for treatment line could require clarification.

**Assessment:**
> The patient's cancer type and mutation match the trial's target indication for KRAS G12C. The patient is of appropriate age and ECOG status. While the patient has received prior treatments, this trial appears to include previously treated patients; however, confirmation of all organ functions is a minor uncertainty.

---

### [NCT05815173](https://clinicaltrials.gov/study/NCT05815173)

**Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: NYU Langone Health
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Age: 58
- Sex: female
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- Prior therapies: docetaxel, ramucirumab
- Brain metastases: stable
- Country: United States

**âœ— Potential Conflicts:**
- Patient has PD-L1 TPS <1%, but trial requires documented progression of disease following treatment with anti-PD (L)-1.
- Mild anemia (Hgb 10.2) may not meet the hemoglobin eligibility criteria of â‰¥8 g/dL without transfusion.

**? Uncertainties:**
- Absolute neutrophil count
- Platelets
- Albumin
- Lymphocyte count
- Serum bilirubin
- AST and ALT
- International normalization ratio (INR)
- Renal clearance (eGFR)

**Assessment:**
> The patient's cancer type (NSCLC with KRAS G12C mutation) matches the trial's focus. The patient is 58 years old and has an ECOG status of 1, fitting into the inclusion criteria. There are uncertainties regarding laboratory values, but the primary reasons for exclusion relate to her prior treatments and PD-L1 status, which may disqualify her despite matching the other criteria.

---

## ðŸŸ¡ MEDIUM Likelihood (7 trials)

### [NCT05074810](https://clinicaltrials.gov/study/NCT05074810)

**A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: Verastem, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Age >= 18
- Histologic evidence of NSCLC (adenocarcinoma)
- Known KRAS G12C mutation
- ECOG performance status 1
- Received prior systemic regimen (docetaxel/ramucirumab)

**âœ— Potential Conflicts:**
- Patient has received prior therapy but trial requires either untreated patients or those exposed to a KRAS inhibitor, which isn't specified as applicable in their case.

**? Uncertainties:**
- Measurable disease status according to RECIST 1.1
- Adequate organ function and recovery from previous treatments (labs not provided)

**Assessment:**
> The patient's cancer type matches the trial's indication, and they have the required KRAS G12C biomarker. However, there's uncertainty regarding the specifics of their treatment history in relation to eligibility criteria for prior therapy exposure and measurable disease status.

---

### [NCT04956640](https://clinicaltrials.gov/study/NCT04956640)

**A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient has NSCLC (adenocarcinoma) which is included in the trial conditions.
- Patient has KRAS G12C mutation.

**âœ— Potential Conflicts:**
- Patient has previously received systemic treatments (docetaxel and ramucirumab), which may conflict with trial's requirement for treatment-naive patients.

**? Uncertainties:**
- Adequate organ function not explicitly stated in lab results.
- Specific criteria regarding the resolution of adverse events from prior therapies not confirmed.

**Assessment:**
> Patient's cancer type (NSCLC) and biomarker (KRAS G12C) match the trial requirements. However, the patient's prior systemic treatment raises concerns about eligibility, necessitating further validation of treatment line requirements and organ function status.

---

### [NCT05799274](https://clinicaltrials.gov/study/NCT05799274)

**Characterizing the Radiochemical and Radiation Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Ductal Adenocarcinoma or Other Solid Tumors**

- **Sponsor**: Radiopharm Theranostics, Ltd
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Age â‰¥ 18 years
- ECOG status 1
- Histologically confirmed NSCLC
- Stable brain metastases off steroids for 3 months

**âœ— Potential Conflicts:**
- Prior therapies (docetaxel, ramucirumab) imply that the patient is not treatment-naive, which could be a conflict depending on the trial's intent for treatment line

**? Uncertainties:**
- Specific screening laboratory values (WBC, ANC, Platelets, Hemoglobin, Creatinine, AST/ALT, Bilirubin) are not provided
- Life expectancy assessment by the investigator is not provided
- Baseline pulse oximetry is not provided
- ECG results are not provided

**Assessment:**
> The patient has a confirmed diagnosis of NSCLC, but they are not treatment-naive, as they have previously received docetaxel and ramucirumab, which raises questions about eligibility given the potential treatment line requirements of the trial. There are also several uncertainties regarding lab values and other eligibility criteria that need clarification.

---

### [NCT05985655](https://clinicaltrials.gov/study/NCT05985655)

**A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors**

- **Sponsor**: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 62%

**âœ“ Supporting Factors:**
- Age: 58
- Sex: female
- Cancer type: NSCLC
- ECOG status: 1

**âœ— Potential Conflicts:**
- Biomarker: PD-L1 TPS <1% does not meet required levels for some trials
- Prior therapies: Has prior treatments which may conflict with eligibility criteria depending on the trial's specification of treatment line.

**? Uncertainties:**
- Adequate hematological function - no lab results stated for liver and renal function

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's conditions, and the ECOG status is acceptable. However, there are conflicts regarding biomarker status (PD-L1 TPS) and prior therapies potentially influencing eligibility. There are uncertainties regarding organ function lab results.

---

### [NCT06907615](https://clinicaltrials.gov/study/NCT06907615)

**An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)**

- **Sponsor**: Shanghai Henlius Biotech
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 55%

**âœ“ Supporting Factors:**
- Metastatic non-small cell lung cancer (NSCLC)
- ECOG status of 1
- Prior treatment failure with docetaxel and ramucirumab

**âœ— Potential Conflicts:**
- PD-L1 TPS <1% does not meet the requirement for PD-L1 expression
- Presence of STK11 co-mutation may be an actionable genomic alteration

**? Uncertainties:**
- Specific requirements for organ function and lab results
- Possible need for additional testing for EGFR and ALK alterations

**Assessment:**
> The patient's cancer type of NSCLC matches the trial's indication. However, key criteria concerning PD-L1 expression and possible actionable genomic alterations introduce uncertainties in eligibility. While the patient has failed first-line therapies, the PD-L1 status being below the required threshold presents a significant conflict.

---

### [NCT06720987](https://clinicaltrials.gov/study/NCT06720987)

**A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations**

- **Sponsor**: Kumquat Biosciences Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 50%

**âœ“ Supporting Factors:**
- Patient has NSCLC, which is a solid tumor malignancy.
- Patient has KRAS G12C mutation.

**âœ— Potential Conflicts:**
- Patient is not treatment-naive, having previously been treated with docetaxel and ramucirumab.

**? Uncertainties:**
- Details about patient organ function labs are not provided.

**Assessment:**
> The patient's cancer type (NSCLC) matches the indication for solid tumor malignancies, and she has the required KRAS G12C mutation. However, she has previous treatments, which may conflict with the trial's inclusion criteria regarding treatment lines.

---

### [NCT06262321](https://clinicaltrials.gov/study/NCT06262321)

**Phase II Trial of Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax**

- **Sponsor**: University of Rochester
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 40%

**âœ“ Supporting Factors:**
- Patient has metastatic Non-Small Cell Lung Cancer (NSCLC)
- Patient has stable brain metastases after SRS treatment
- Patient has received prior systemic therapy
- Patient's ECOG status is 1

**âœ— Potential Conflicts:**
- Patient has a KRAS G12C mutation, which is a targetable/oncogene driven mutation and conflicts with inclusion criteria stating no targetable mutations.

**Assessment:**
> The patient has the correct cancer type (NSCLC) but is excluded due to having a targetable mutation (KRAS G12C), conflicting with trial eligibility criteria.

---

## ðŸŸ  LOW Likelihood (5 trials)

### [NCT05501665](https://clinicaltrials.gov/study/NCT05501665)

**SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II Study**

- **Sponsor**: Vanderbilt-Ingram Cancer Center
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Age is 58 years, which meets the age requirement (>= 18 years)
- ECOG status is 1, which is within the acceptable range (0-2)
- Patient has a confirmed diagnosis of NSCLC, which aligns with the trial conditions

**âœ— Potential Conflicts:**
- Patient has received prior treatments (docetaxel and ramucirumab) while trial is for previously treated patients but not specified otherwise
- Patient's PD-L1 expression is <1%, which does not meet the trial's requirements for PD-L1 expression confirmation

**Assessment:**
> The patient's cancer type matches, but they have previously received treatment and have a PD-L1 expression of <1%, leading to significant doubts about eligibility.

---

### [NCT05800587](https://clinicaltrials.gov/study/NCT05800587)

**Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities**

- **Sponsor**: Fox Chase Cancer Center
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Patient has metastatic NSCLC (adenocarcinoma), which is included in the study conditions.

**âœ— Potential Conflicts:**
- Patient is not treatment-naive; failed first-line therapies (docetaxel, ramucirumab).
- PD-L1 TPS <1%, which may be a concern if the study has specific PD-L1 requirements.

**? Uncertainties:**
- No information on specific cytotoxic chemotherapy regimens planned for the patient.
- No specific details on other comorbidities or their severity in relation to trial eligibility.

**Assessment:**
> The patient's cancer type (NSCLC) aligns with the trial's conditions. However, the patient is not treatment-naive due to prior therapies, which conflicts with the requirement for previously treated patients. Additionally, the low PD-L1 status adds an element of uncertainty regarding eligibility.

---

### [NCT06881784](https://clinicaltrials.gov/study/NCT06881784)

**RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 20%

**âœ“ Supporting Factors:**
- ECOG status is 1
- Pathologically confirmed NSCLC
- Documented RAS mutation status (KRAS G12C)

**âœ— Potential Conflicts:**
- Prior therapy with docetaxel, which is excluded by the trial
- Prior therapy with ramucirumab, which is excluded by the trial

**? Uncertainties:**
- Adequate organ function is not explicitly confirmed
- Co-morbidities or significant cardiovascular issues are not fully detailed

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial criteria, but she has prior therapy with docetaxel and ramucirumab, which excludes her from the trial. There are further uncertainties regarding her organ function and comorbidities.

---

### [NCT05254184](https://clinicaltrials.gov/study/NCT05254184)

**Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer**

- **Sponsor**: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 20%

**âœ“ Supporting Factors:**
- Patient has metastatic NSCLC (adenocarcinoma) which is a targeted condition for the trial.
- Patient has KRAS G12C mutation which is required for the trial.
- ECOG status of 1 is acceptable for trial eligibility.

**âœ— Potential Conflicts:**
- Patient is not treatment-naive as they have received prior therapies: docetaxel and ramucirumab which contradicts the trial's requirement for no prior therapy for the same stage of disease.

**Assessment:**
> The patient's cancer type aligns with the trial's focus on KRAS mutated NSCLC. However, the patient has previously received treatment which conflicts with the trial's requirement for treatment-naive participants, leading to a likely exclusion.

---

### [NCT06131840](https://clinicaltrials.gov/study/NCT06131840)

**An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors**

- **Sponsor**: Seagen, a wholly owned subsidiary of Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 20%

**âœ“ Supporting Factors:**
- Patient has NSCLC which is a target tumor type in the trial.
- ECOG status is 1.

**âœ— Potential Conflicts:**
- Patient has already received prior systemic therapy (docetaxel/ramucirumab). This trial requires no appropriate standard therapy available.
- PD-L1 TPS <1% does not meet the requirement for receiving PD-1/PD-L1 inhibitors.

**? Uncertainties:**
- Molecular requirements related to additional biomarkers if mentioned in trial specifics.
- Details on organ function or standard lab results are not provided.

**Assessment:**
> The patient's cancer type (NSCLC) fits the trial's criteria. However, the patient has previously been treated, which disqualifies them given the trial's requirement for having no appropriate standard therapy available. This leads to a clear exclusion based on treatment history.

---

## Excluded (70 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT02143830](https://clinicaltrials.gov/study/NCT02143830) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04589845](https://clinicaltrials.gov/study/NCT04589845) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05058651](https://clinicaltrials.gov/study/NCT05058651) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05638295](https://clinicaltrials.gov/study/NCT05638295) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05684965](https://clinicaltrials.gov/study/NCT05684965) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06730750](https://clinicaltrials.gov/study/NCT06730750) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03420963](https://clinicaltrials.gov/study/NCT03420963) | Patient age 58 is above maximum age 40 |
| [NCT04423029](https://clinicaltrials.gov/study/NCT04423029) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04929223](https://clinicaltrials.gov/study/NCT04929223) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05738252](https://clinicaltrials.gov/study/NCT05738252) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06475807](https://clinicaltrials.gov/study/NCT06475807) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06804824](https://clinicaltrials.gov/study/NCT06804824) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06807619](https://clinicaltrials.gov/study/NCT06807619) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT05118854](https://clinicaltrials.gov/study/NCT05118854) | M.D. Anderson Cancer | Patient has previously treated NSCLC (docetaxel and ramucirumab), while trial is for untreated or treatment-naive patients. |
| [NCT05853575](https://clinicaltrials.gov/study/NCT05853575) | Mirati Therapeutics  | Patient has not received treatment with cisplatin or carboplatin as required by the trial criteria. |
| [NCT05920356](https://clinicaltrials.gov/study/NCT05920356) | Amgen | Patient has prior systemic therapy (docetaxel and ramucirumab) despite the trial requiring no history of systemic anticancer therapy in metastatic settings. |
| [NCT06345729](https://clinicaltrials.gov/study/NCT06345729) | Merck Sharp & Dohme  | Trial requires treatment-naive patients, but patient has received prior systemic therapy (docetaxel, ramucirumab) |
| [NCT06452277](https://clinicaltrials.gov/study/NCT06452277) | Bayer | Patient has NSCLC with KRAS G12C mutation; trial targets NSCLC with HER2 mutations. |
| [NCT06582771](https://clinicaltrials.gov/study/NCT06582771) | Memorial Sloan Kette | Patient has received prior therapies (docetaxel and ramucirumab) whereas the trial requires treatment-naive patients. |
| [NCT06644768](https://clinicaltrials.gov/study/NCT06644768) | Daiichi Sankyo | Patient has prior systemic therapy (docetaxel and ramucirumab) for advanced disease, while the trial requires treatment-naive patients. |
| [NCT06667076](https://clinicaltrials.gov/study/NCT06667076) | Janssen Research & D | Patient has KRAS G12C mutation; trial requires EGFRm which must be Ex19del or Ex21 L858R substitution. |
| [NCT06660407](https://clinicaltrials.gov/study/NCT06660407) | Mayo Clinic | Patient has progressed after previous treatments (docetaxel and ramucirumab), whereas the trial is looking for patients progressing on standard of care immunotherapy or chemoimmunotherapy. |
| [NCT06875310](https://clinicaltrials.gov/study/NCT06875310) | Mirati Therapeutics  | Patient has prior systemic therapy (docetaxel, ramucirumab) for advanced disease, but the trial requires treatment-naive patients. |
| [NCT06712316](https://clinicaltrials.gov/study/NCT06712316) | BioNTech SE | Patient has received prior therapies (docetaxel, ramucirumab), while the trial is for first-line NSCLC |
| [NCT06890598](https://clinicaltrials.gov/study/NCT06890598) | Eli Lilly and Compan | Patient has prior therapies (docetaxel, ramucirumab), while the trial's part A requires treatment-naive or first-line patients. |
| [NCT06793215](https://clinicaltrials.gov/study/NCT06793215) | Hoffmann-La Roche | Patient has received prior systemic treatment (docetaxel and ramucirumab), whereas trial requires treatment-naive status |
| [NCT07063745](https://clinicaltrials.gov/study/NCT07063745) | Bristol-Myers Squibb | Patient has prior systemic therapy (docetaxel, ramucirumab) for metastatic NSCLC, but trial requires treatment-naive patients. |
| [NCT07012031](https://clinicaltrials.gov/study/NCT07012031) | National Cancer Inst | Trial requires prior treatment with a KRAS G12C inhibitor, but patient has not received one. |
| [NCT07190248](https://clinicaltrials.gov/study/NCT07190248) | Merck Sharp & Dohme  | Patient has received prior systemic anticancer therapy for their advanced or metastatic NSCLC |
| [NCT00897117](https://clinicaltrials.gov/study/NCT00897117) | Vanderbilt-Ingram Ca | Patient has previously treated metastatic NSCLC; trial requires treatment-naive patients. |
| [NCT03551951](https://clinicaltrials.gov/study/NCT03551951) | University of Missou | Patient has previously received systemic therapy (docetaxel and ramucirumab), while the trial eligibility is presumed for treatment-naive patients. |
| [NCT02570815](https://clinicaltrials.gov/study/NCT02570815) | St. Joseph's Healthc | Patient has metastatic NSCLC, but trial is for early stage (Clinical Stage 1) NSCLC. |
| [NCT03260491](https://clinicaltrials.gov/study/NCT03260491) | Daiichi Sankyo | Patient has a history of prior treatments (docetaxel, ramucirumab) whereas the trial enrollment for Dose Escalation specifically requires acquired resistance to EGFR TKI, and the trial does not state universal eligibility for previously treated patients. |
| ... | ... | *and 36 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12C | manual | 1.0 |
| KRASG12C | manual | 0.9 |
| KRAS-G12C | manual | 0.9 |
| NSCLC | manual | 1.0 |
| KRAS G12C NSCLC | manual | 1.0 |
| KRAS G12C non-small cell lung cancer | llm | 0.9 |
| KRAS G12C lung adenocarcinoma | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |
| lung adenocarcinoma | llm | 0.8 |
| KRAS p.G12C | llm | 0.9 |
| KRASp.G12C | llm | 0.8 |
| KRAS-p.G12C | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
- **Life expectancy estimate** - many trials require â‰¥3 months
- **Cardiac status/QTc interval** - relevant for trials with cardiotoxicity risk
